Five monoclonal antibodies (mAb) targeting some molecules participating in type 2 (T2) inflammation (i.e., anti-IL4/13, anti-IL-5, anti-IL-5Rα, anti-IgE, anti-thymic stromal lymphopoietin (TSLP)) are now available for severe asthma and some of them are also indicated for CRSwNP. The gene discussed is IL4; the disease is asthma.